{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:54:26Z","timestamp":1772582066321,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M731847"],"award-info":[{"award-number":["2023M731847"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Technology Research and Development Programme of China","award":["2022YFC2704304"],"award-info":[{"award-number":["2022YFC2704304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36534-x","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:23:44Z","timestamp":1772533424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening"],"prefix":"10.1038","volume":"16","author":[{"given":"Xinyue","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shourong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binglin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"36534_CR1","doi-asserted-by":"crossref","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. Cancer J. Clin. 74(1), 12\u201349 (2024).","DOI":"10.3322\/caac.21820"},{"issue":"1","key":"36534_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-025-00803-1","volume":"9","author":"PJ Haight","year":"2025","unstructured":"Haight, P. J. et al. Molecular characterization of mixed-histology endometrial carcinoma provides prognostic and therapeutic value over morphologic findings. NPJ Precision Oncol. 9(1), 41 (2025).","journal-title":"NPJ Precision Oncol."},{"issue":"9","key":"36534_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio, M. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study. Ann. Oncol. 33(9), 929\u2013938 (2022).","journal-title":"Ann. Oncol."},{"issue":"21","key":"36534_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-Year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion Score\u2009\u2265\u200950. J. Clin. Oncol. 39(21), 2339\u20132349 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"36534_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Maintenance Olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22(12), 1721\u20131731 (2021).","journal-title":"Lancet Oncol."},{"issue":"11","key":"36534_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 35(11), 981\u2013992 (2024).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"6","key":"36534_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N. Engl. J. Med. 389(6), 491\u2013503 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"36534_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro, P. et al. Overall survival with maintenance Olaparib at a 7-Year Follow-Up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 41(3), 609\u2013617 (2023).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"36534_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajog.2024.07.018","volume":"231","author":"Y Suzuki","year":"2024","unstructured":"Suzuki, Y. et al. Fertility-preserving treatment for stage IA endometrial cancer: A systematic review and meta-analysis. Am. J. Obstet. Gynecol. 231(6), 599\u2013610e17 (2024).","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"36534_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41588-024-01703-z","volume":"56","author":"Z Hu","year":"2024","unstructured":"Hu, Z. et al. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: Predictors for fertility-sparing therapy response. Nat. Genet. 56(4), 637\u2013651 (2024).","journal-title":"Nat. Genet."},{"issue":"7","key":"36534_CR11","first-page":"Cd013111","volume":"7","author":"ME Fernandez-Montoli","year":"2025","unstructured":"Fernandez-Montoli, M. E. et al. Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Cochrane Database Syst. Rev. 7(7), Cd013111 (2025).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"36534_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","volume":"125","author":"J Baker","year":"2012","unstructured":"Baker, J., Obermair, A., Gebski, V. & Janda, M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol. Oncol. 125(1), 263\u2013270 (2012).","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"36534_CR13","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/ijms23052531","volume":"23","author":"N-A Contreras","year":"2022","unstructured":"Contreras, N-A., Sabadell, J., Verdaguer, P., Juli\u00e0, C. & Fern\u00e1ndez-Montol\u00ed, M-E. Fertility-Sparing approaches in atypical endometrial hyperplasia and endometrial cancer patients: current evidence and future directions. Int. J. Mol. Sci. 23(5), 2531 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"36534_CR14","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.3390\/cancers14246210","volume":"14","author":"M Lv","year":"2022","unstructured":"Lv, M. et al. Progestin resistance and corresponding management of abnormal endometrial hyperplasia and endometrial carcinoma. Cancers (Basel). 14(24), 6210 (2022).","journal-title":"Cancers (Basel)"},{"issue":"15","key":"36534_CR15","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.3390\/ijms20153822","volume":"20","author":"RM Marquardt","year":"2019","unstructured":"Marquardt, R. M., Kim, T. H., Shin, J-H. & Jeong, J-W. Progesterone and Estrogen signaling in the endometrium: what goes wrong in endometriosis? Int. J. Mol. Sci. 20(15), 3822 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"36534_CR16","doi-asserted-by":"publisher","first-page":"9783","DOI":"10.18632\/oncotarget.2392","volume":"5","author":"S Yang","year":"2014","unstructured":"Yang, S. et al. Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer. Oncotarget 5(20), 9783\u20139797 (2014).","journal-title":"Oncotarget"},{"key":"36534_CR17","doi-asserted-by":"crossref","unstructured":"Upson, K. et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am. J. Obstet. Gynecol. 207(1), 36.e1\u2013.e8 (2012).","DOI":"10.1016\/j.ajog.2012.05.012"},{"issue":"1","key":"36534_CR18","first-page":"97","volume":"61","author":"M Sasaki","year":"2001","unstructured":"Sasaki, M. et al. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 61(1), 97\u2013102 (2001).","journal-title":"Cancer Res."},{"issue":"9","key":"36534_CR19","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1002\/cam4.2317","volume":"8","author":"Q Zhou","year":"2019","unstructured":"Zhou, Q. et al. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma. Cancer Med. 8(9), 4380\u20134388 (2019).","journal-title":"Cancer Med."},{"key":"36534_CR20","doi-asserted-by":"publisher","first-page":"108939","DOI":"10.1016\/j.biopha.2019.108939","volume":"115","author":"Q Lin","year":"2019","unstructured":"Lin, Q., Chen, H., Zhang, M., Xiong, H. & Jiang, Q. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by Silencing the PI3K\/AKT\/mTOR pathway. Biomed. Pharmacother. 115, 108939 (2019).","journal-title":"Biomed. Pharmacother"},{"issue":"2","key":"36534_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0090-8258(02)00008-2","volume":"88","author":"S Wang","year":"2003","unstructured":"Wang, S. et al. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia\u2013precursor of endometrial cancer. Gynecol. Oncol. 88(2), 108\u2013117 (2003).","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"36534_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.mce.2011.10.035","volume":"358","author":"M Al-Sabbagh","year":"2012","unstructured":"Al-Sabbagh, M., Lam, E. W. F. & Brosens, J. J. Mechanisms of endometrial progesterone resistance. Mol. Cell. Endocrinol. 358(2), 208\u2013215 (2012).","journal-title":"Mol. Cell. Endocrinol."},{"issue":"15","key":"36534_CR23","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1002\/cncr.25220","volume":"116","author":"Z Ai","year":"2010","unstructured":"Ai, Z. et al. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR\/mitogen-activated protein kinase signaling pathway. Cancer 116(15), 3603\u20133613 (2010).","journal-title":"Cancer"},{"issue":"1","key":"36534_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12967-019-1814-6","volume":"17","author":"W Li","year":"2019","unstructured":"Li, W. et al. Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line. J. Transl. Med. 17(1), 58 (2019).","journal-title":"J. Transl Med."},{"issue":"12","key":"36534_CR25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41419-022-05507-z","volume":"13","author":"X Ma","year":"2022","unstructured":"Ma, X. et al. ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL. Cell Death Dis. 13(12), 1067 (2022).","journal-title":"Cell. Death Dis."},{"issue":"6","key":"36534_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41419-021-03762-0","volume":"12","author":"X Ma","year":"2021","unstructured":"Ma, X. et al. Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-\u03baB pathway in endometrial carcinoma. Cell Death Dis. 12(6), 544 (2021).","journal-title":"Cell. Death Dis."},{"issue":"7439","key":"36534_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/495050a","volume":"495","author":"E Charpentier","year":"2013","unstructured":"Charpentier, E., Doudna, J. A. & Biotechnology Rewriting a genome. Nature 495(7439), 50\u201351 (2013).","journal-title":"Nature"},{"key":"36534_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang, F. & Doudna, J. A. CRISPR-Cas9 structures and mechanisms. Annu. Rev. Biophys. 46, 505\u2013529 (2017).","journal-title":"Annu. Rev. Biophys."},{"issue":"9","key":"36534_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nbt.3659","volume":"34","author":"R Barrangou","year":"2016","unstructured":"Barrangou, R. & Doudna, J. A. Applications of CRISPR technologies in research and beyond. Nat. Biotechnol. 34(9), 933\u2013941 (2016).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"36534_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrn.2015.2","volume":"17","author":"M Heidenreich","year":"2016","unstructured":"Heidenreich, M. & Zhang, F. Applications of CRISPR-Cas systems in neuroscience. Nat. Rev. Neurosci. 17(1), 36\u201344 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"36534_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-genom-083115-022258","volume":"17","author":"X Xiong","year":"2016","unstructured":"Xiong, X., Chen, M., Lim, W. A., Zhao, D. & Qi, L. S. CRISPR\/Cas9 for human genome engineering and disease research. Annu. Rev. Genomics Hum. Genet. 17, 131\u2013154 (2016).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"3","key":"36534_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41596-018-0113-7","volume":"14","author":"B Wang","year":"2019","unstructured":"Wang, B. et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat. Protoc. 14(3), 756\u2013780 (2019).","journal-title":"Nat. Protoc."},{"issue":"1","key":"36534_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41419-025-07697-8","volume":"16","author":"R Sun","year":"2025","unstructured":"Sun, R. et al. Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1\/YAP1 axis. Cell Death Dis. 16(1), 380 (2025).","journal-title":"Cell Death Dis."},{"issue":"12","key":"36534_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15(12), 554 (2014).","journal-title":"Genome Biol."},{"issue":"1","key":"36534_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"36534_CR36","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. Publ. Protein Soc. 28(11), 1947\u20131951 (2019).","journal-title":"Protein Science: Publication Protein Soc."},{"issue":"D1","key":"36534_CR37","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53(D1), D672\u2013d7 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"24","key":"36534_CR38","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.3390\/cancers14246210","volume":"14","author":"M Lv","year":"2022","unstructured":"Lv, M. et al. Progestin resistance and corresponding management of abnormal endometrial hyperplasia and endometrial carcinoma. Cancers 14(24), 6210 (2022).","journal-title":"Cancers"},{"issue":"2","key":"36534_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/1471-0528.17331","volume":"130","author":"WJ van Weelden","year":"2023","unstructured":"van Weelden, W. J. et al. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis. BJOG: Int. J. Obstet. Gynecol. 130(2), 143\u2013152 (2023).","journal-title":"BJOG: Int. J. Obstet. Gynecol."},{"issue":"4","key":"36534_CR40","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ejca.2012.09.017","volume":"49","author":"J-Y Park","year":"2013","unstructured":"Park, J-Y. et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur. J. Cancer. 49(4), 868\u2013874 (2013).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"36534_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","volume":"125","author":"CC Gunderson","year":"2012","unstructured":"Gunderson, C. C., Fader, A. N., Carson, K. A. & Bristow, R. E. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol. Oncol. 125(2), 477\u2013482 (2012).","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"36534_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/1471-0528.17331","volume":"130","author":"WJ van Weelden","year":"2023","unstructured":"van Weelden, W. J. et al. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis. BJOG 130(2), 143\u2013152 (2023).","journal-title":"BJOG"},{"key":"36534_CR43","doi-asserted-by":"publisher","first-page":"665832","DOI":"10.3389\/fonc.2021.665832","volume":"11","author":"Y Cui","year":"2021","unstructured":"Cui, Y. et al. Chlorpromazine sensitizes Progestin-Resistant endometrial cancer cells to MPA by upregulating PRB. Front. Oncol. 11, 665832 (2021).","journal-title":"Front. Oncol."},{"issue":"11","key":"36534_CR44","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.2174\/13816128113199990532","volume":"20","author":"S Yang","year":"2014","unstructured":"Yang, S. et al. Epigenetic modification restores functional PR expression in endometrial cancer cells. Curr. Pharm. Des. 20(11), 1874\u20131880 (2014).","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"36534_CR45","first-page":"220","volume":"25","author":"Y Boumber","year":"2011","unstructured":"Boumber, Y. & Issa, J-P-J. Epigenetics in cancer: what\u2019s the future? Oncol. (Williston Park). 25(3), 220 (2011).","journal-title":"Oncol. (Williston Park)"},{"issue":"3","key":"36534_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1349-7006.2010.01829.x","volume":"102","author":"C Gu","year":"2011","unstructured":"Gu, C. et al. Inhibiting the PI3K\/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci. 102(3), 557\u2013564 (2011).","journal-title":"Cancer Sci."},{"issue":"7","key":"36534_CR47","doi-asserted-by":"publisher","first-page":"e41593","DOI":"10.1371\/journal.pone.0041593","volume":"7","author":"A Pant","year":"2012","unstructured":"Pant, A. et al. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One. 7(7), e41593 (2012).","journal-title":"PLoS One"},{"issue":"24","key":"36534_CR48","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","volume":"29","author":"AM Oza","year":"2011","unstructured":"Oza, A. M. et al. Phase II study of Temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J. Clin. Oncol. 29(24), 3278\u20133285 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"3\u20134","key":"36534_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10495-021-01657-1","volume":"26","author":"L McGlorthan","year":"2021","unstructured":"McGlorthan, L., Paucarmayta, A., Casablanca, Y., Maxwell, G. L. & Syed, V. Progesterone induces apoptosis by activation of caspase-8 and calcitriol via activation of caspase-9 pathways in ovarian and endometrial cancer cells in vitro. Apoptosis 26(3\u20134), 184\u2013194 (2021).","journal-title":"Apoptosis"},{"issue":"6","key":"36534_CR50","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/humupd\/dmab017","volume":"27","author":"SE Bulun","year":"2021","unstructured":"Bulun, S. E., Yildiz, S., Adli, M. & Wei, J-J. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum. Reprod. Update 27(6), 1086\u20131097 (2021).","journal-title":"Hum. Reprod. Update"},{"issue":"8","key":"36534_CR51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.tem.2018.05.006","volume":"29","author":"B McKinnon","year":"2018","unstructured":"McKinnon, B., Mueller, M. & Montgomery, G. Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol. Metab. 29(8), 535\u2013548 (2018).","journal-title":"Trends Endocrinol. Metab."},{"issue":"15","key":"36534_CR52","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.3390\/ijms22158129","volume":"22","author":"M. Matboli","year":"2021","unstructured":"Matboli, M. et al. Identification of novel insulin resistance related CeRNA network in T2DM and its potential editing by CRISPR\/Cas9. Int. J. Mol. Sci. 22(15), 8129 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"36534_CR53","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41416-023-02347-2","volume":"129","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z., Zhang, M., Zhou, J. & Wang, D. Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy. Br. J. Cancer. 129, 601\u2013611 (2023).","journal-title":"Br. J. Cancer"},{"issue":"12","key":"36534_CR54","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","volume":"14","author":"M Widschwendter","year":"2013","unstructured":"Widschwendter, M. et al. The sex hormone system in carriers of BRCA1\/2 mutations: A case-control study. Lancet Oncol. 14(12), 1226\u20131232 (2013).","journal-title":"Lancet Oncol."},{"issue":"4","key":"36534_CR55","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ajog.2020.10.003","volume":"224","author":"YS Chung","year":"2021","unstructured":"Chung, Y. S. et al. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. Am. J. Obstet. Gynecol. 224(4), 370\u2013e1 (2021).","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"7495","key":"36534_CR56","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature13198","volume":"508","author":"D Kraus","year":"2014","unstructured":"Kraus, D. et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508(7495), 258\u2013262 (2014).","journal-title":"Nature"},{"issue":"7758","key":"36534_CR57","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41586-019-1173-8","volume":"569","author":"MA Eckert","year":"2019","unstructured":"Eckert, M. A. et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature 569(7758), 723\u2013728 (2019).","journal-title":"Nature"},{"issue":"Pt 1","key":"36534_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2019.08.008","volume":"67","author":"DS Tan","year":"2020","unstructured":"Tan, D. S., Holzner, M., Weng, M., Srivastava, Y. & Jauch, R. SOX17 in cellular reprogramming and cancer. Semin. Cancer Biol. 67(Pt 1), 65\u201373 (2020).","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"36534_CR59","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/s41388-022-02210-3","volume":"41","author":"L Lin","year":"2022","unstructured":"Lin, L. et al. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer. Oncogene 41(12), 1767\u20131779 (2022).","journal-title":"Oncogene"},{"issue":"7","key":"36534_CR60","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41419-018-0782-8","volume":"9","author":"L Li","year":"2018","unstructured":"Li, L., Yang, W-T., Zheng, P-S. & Liu, X-F. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt\/\u03b2-catenin signaling pathway via trans-suppressing \u03b2-catenin in cervical cancer. Cell Death Dis. 9(7), 741 (2018).","journal-title":"Cell Death Dis."},{"issue":"4","key":"36534_CR61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00280-020-04143-8","volume":"86","author":"C Teng","year":"2020","unstructured":"Teng, C. et al. Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: A pilot study assessing preliminary efficacy, tolerability and Pharmacokinetic interactions in patients with metastatic Gastrointestinal cancer. Cancer Chemother. Pharmacol. 86(4), 547\u2013558 (2020).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36534-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36534-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36534-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:02:23Z","timestamp":1772578943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36534-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36534"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36534-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study doesn\u2019t involve any human participants, human data or human tissue. This study was approved by the Research Ethics Committee of Qilu Hospital of Shandong University. (KYLL-202210-055-1). All procedures involving nude mice were performed in accordance with institutional guidelines and national regulations on the care and use of laboratory animals. The study is reported in accordance with the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"8030"}}